MX2018000872A - Combinaciones terapeuticas de paclitaxel oralmente administrado y un inhibidor de la bomba de p-glicoproteina (p-gp) para el tratamiento del cancer. - Google Patents
Combinaciones terapeuticas de paclitaxel oralmente administrado y un inhibidor de la bomba de p-glicoproteina (p-gp) para el tratamiento del cancer.Info
- Publication number
- MX2018000872A MX2018000872A MX2018000872A MX2018000872A MX2018000872A MX 2018000872 A MX2018000872 A MX 2018000872A MX 2018000872 A MX2018000872 A MX 2018000872A MX 2018000872 A MX2018000872 A MX 2018000872A MX 2018000872 A MX2018000872 A MX 2018000872A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- inhibitor
- treatment
- orally administered
- administered paclitaxel
- Prior art date
Links
- 229930012538 Paclitaxel Natural products 0.000 title abstract 5
- 229960001592 paclitaxel Drugs 0.000 title abstract 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 title abstract 5
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title 1
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 abstract 1
- 101001017818 Homo sapiens ATP-dependent translocase ABCB1 Proteins 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 230000009610 hypersensitivity Effects 0.000 abstract 1
- 238000001802 infusion Methods 0.000 abstract 1
- 239000008389 polyethoxylated castor oil Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La solicitud se refiere a combinaciones farmacéuticas de paclitaxel oralmente administrado y a un inhibidor de P-gp; las combinaciones farmacéuticas son adecuadas para el tratamiento de cáncer en un sujeto y para reducir o prevenir reacciones por infusión de tipo toxicidad, hipersensibilidad y otros resultados negativos que se deriven o estén asociados con terapia de paclitaxel administrado vía intravenosa (por ejemplo,Taxol(r) o paclitaxel formulado con Cremophor(r)) en un sujeto que padece cáncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562195243P | 2015-07-21 | 2015-07-21 | |
| PCT/IB2016/001132 WO2017013490A2 (en) | 2015-07-21 | 2016-07-21 | Therapeutic combinations of orally administered paclitaxel and a p-gp inhibitor for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018000872A true MX2018000872A (es) | 2018-08-15 |
| MX389270B MX389270B (es) | 2025-03-20 |
Family
ID=57833861
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018000872A MX389270B (es) | 2015-07-21 | 2016-07-21 | Combinaciones terapéuticas de paclitaxel oralmente administrado y un inhibidor de la bomba de p-glicoproteína (p-gp) para el tratamiento del cáncer. |
| MX2022000394A MX2022000394A (es) | 2015-07-21 | 2018-01-19 | Combinaciones terapeuticas de paclitaxel oralmente administrado y un inhibidor de la bomba de p-glicoproteina (p-gp) para el tratamiento del cancer. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022000394A MX2022000394A (es) | 2015-07-21 | 2018-01-19 | Combinaciones terapeuticas de paclitaxel oralmente administrado y un inhibidor de la bomba de p-glicoproteina (p-gp) para el tratamiento del cancer. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20180207148A1 (es) |
| EP (1) | EP3324968B1 (es) |
| CN (2) | CN108135895A (es) |
| AU (3) | AU2016295357B2 (es) |
| CA (1) | CA2993127C (es) |
| JO (1) | JO3737B1 (es) |
| MX (2) | MX389270B (es) |
| TW (1) | TWI760306B (es) |
| WO (1) | WO2017013490A2 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI752750B (zh) * | 2015-09-30 | 2022-01-11 | 香港商慧源香港創新有限公司 | 口服紫杉烷組合物及方法 |
| WO2019200290A1 (en) * | 2018-04-13 | 2019-10-17 | Athenex Therapeutics Limited | Therapeutic combinations of orally administered paclitaxel and a p-gp inhibitor for the treatment of angiosarcoma |
| CN113631166A (zh) * | 2018-12-14 | 2021-11-09 | 慧源香港创新有限公司 | 用于治疗癌症的口服给药的伊立替康和P-gp抑制剂的治疗组合 |
| US20240390360A1 (en) * | 2021-09-10 | 2024-11-28 | Athenex, Inc. | Therapeutic Combinations Of Orally Administered Paclitaxel, A P-gp Inhibitor, And A Checkpoint Inhibitor For The Treatment Of Solid Tumors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5968972A (en) * | 1995-10-26 | 1999-10-19 | Baker Norton Pharmaceuticals, Inc. | Method for increasing the oral bioactivity of pharmaceutical agents |
| HUP0203303A3 (en) * | 1999-10-27 | 2005-01-28 | Baker Norton Pharma | Compositions for administering taxanes orally to human patients |
| CN1652822A (zh) * | 2002-05-07 | 2005-08-10 | 奥坦纳医药公司 | 用于治疗气道病症的可逆质子泵抑制剂和气道治疗剂的新组合 |
| KR100557093B1 (ko) * | 2003-10-07 | 2006-03-03 | 한미약품 주식회사 | 다약제 내성 저해 활성을 갖는 테트라졸 유도체 및 그의제조방법 |
| KR101466245B1 (ko) * | 2010-01-15 | 2014-12-01 | 한미사이언스 주식회사 | 테트라졸 메탄설폰산 염의 제조방법 및 이에 사용되는 신규 화합물 |
| US10441544B2 (en) * | 2017-10-10 | 2019-10-15 | Douglas Pharmaceuticals, Ltd. | Extended release pharmaceutical formulation |
| WO2019200290A1 (en) * | 2018-04-13 | 2019-10-17 | Athenex Therapeutics Limited | Therapeutic combinations of orally administered paclitaxel and a p-gp inhibitor for the treatment of angiosarcoma |
-
2016
- 2016-07-20 JO JOP/2016/0149A patent/JO3737B1/ar active
- 2016-07-21 CA CA2993127A patent/CA2993127C/en active Active
- 2016-07-21 WO PCT/IB2016/001132 patent/WO2017013490A2/en not_active Ceased
- 2016-07-21 AU AU2016295357A patent/AU2016295357B2/en active Active
- 2016-07-21 CN CN201680054929.XA patent/CN108135895A/zh active Pending
- 2016-07-21 US US15/745,490 patent/US20180207148A1/en not_active Abandoned
- 2016-07-21 MX MX2018000872A patent/MX389270B/es unknown
- 2016-07-21 CN CN202211612201.8A patent/CN115778956A/zh active Pending
- 2016-07-21 EP EP16827318.3A patent/EP3324968B1/en active Active
- 2016-07-21 TW TW105123085A patent/TWI760306B/zh active
-
2018
- 2018-01-19 MX MX2022000394A patent/MX2022000394A/es unknown
-
2021
- 2021-07-26 AU AU2021209160A patent/AU2021209160A1/en not_active Abandoned
-
2022
- 2022-10-04 US US17/959,470 patent/US20230172926A1/en active Pending
-
2023
- 2023-09-15 AU AU2023229590A patent/AU2023229590A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3324968B1 (en) | 2023-09-27 |
| CA2993127A1 (en) | 2017-01-26 |
| TW201716064A (zh) | 2017-05-16 |
| AU2016295357B2 (en) | 2021-05-13 |
| CA2993127C (en) | 2023-10-17 |
| TWI760306B (zh) | 2022-04-11 |
| CN115778956A (zh) | 2023-03-14 |
| US20180207148A1 (en) | 2018-07-26 |
| WO2017013490A2 (en) | 2017-01-26 |
| WO2017013490A3 (en) | 2017-03-02 |
| EP3324968A2 (en) | 2018-05-30 |
| JO3737B1 (ar) | 2021-01-31 |
| CN108135895A (zh) | 2018-06-08 |
| EP3324968C0 (en) | 2023-09-27 |
| AU2016295357A1 (en) | 2018-02-15 |
| MX2022000394A (es) | 2022-02-10 |
| AU2021209160A1 (en) | 2021-08-19 |
| NZ739270A (en) | 2024-10-25 |
| HK1256017A1 (en) | 2019-09-13 |
| AU2023229590A1 (en) | 2023-10-05 |
| EP3324968A4 (en) | 2019-04-10 |
| US20230172926A1 (en) | 2023-06-08 |
| MX389270B (es) | 2025-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125205T1 (el) | Φαρμακευτικες συνθεσεις δραστικων απο θεραπευτικη αποψη ενωσεων | |
| CL2019000221A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1. | |
| SV2017005489A (es) | Terapias de combinación para el tratamiento de cánceres | |
| MX2016011810A (es) | Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso. | |
| CL2019001214A1 (es) | Composición farmacéutica, métodos para tratamiento y sus usos. | |
| CL2019002240A1 (es) | Dendrímeros terapéuticos. | |
| SV2018005687A (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer | |
| MX2018001723A (es) | Conjugados farmaco-multiligando y usos de los mismos. | |
| MX2022014792A (es) | Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican. | |
| MX2016015434A (es) | Combinaciones farmaceuticas para tratar cancer. | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| MX385762B (es) | Métodos para el control transcripcional objetivo en regiones del super mejorador. | |
| DOP2016000254A (es) | Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso. | |
| MX2017009849A (es) | Composiciones de profármaco de monometilfumarato. | |
| AR094707A1 (es) | Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2 | |
| PH12017502046A1 (en) | Salts and prodrugs of 1-methyl-d-tryptophan | |
| EA201890457A1 (ru) | Комбинации антитела против ox40 и модулятора tlr4 и их применение | |
| MX2018000872A (es) | Combinaciones terapeuticas de paclitaxel oralmente administrado y un inhibidor de la bomba de p-glicoproteina (p-gp) para el tratamiento del cancer. | |
| MX2017010341A (es) | Terapia para cancer con un parvovirus combinado con bevacizumab. | |
| UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 | |
| MX387726B (es) | Derivados de ftalazina como inhibidores de parp1, parp2 y/o tubulina útiles para el tratamiento del cáncer. | |
| MX381526B (es) | Agente para suprimir el progreso de o para mejorar la enfermedad renal crónica. | |
| MX384394B (es) | Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas. | |
| BR112019002213A2 (pt) | composições e o uso das mesmas para tratar ou prevenir rosácea | |
| AR111063A1 (es) | Dendrímeros terapéuticos |